Clinical trials
Malignant Solid Neoplasm clinical trials
Below are recruiting malignant solid neoplasm clinical trials, each written for real people, not researchers. We’re tracking 291 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT05539677Recruiting
Research biobank and patient registry for aggressive solid tumors
This study builds a biobank and patient registry using tumor samples and blood. It helps researchers better understand aggressive cancers and may improve future treatments by testing immune (defense) responses.
Saint PetersburgAges 1 year+ - NCT06438250RecruitingEarly Phase 1
Studying a new imaging agent for solid tumors
This trial tests a new imaging agent called 68Ga-JH04 that is used with a PET/CT scan. The goal is to see how the agent travels through the body and how much radiation it gives off, which may help doctors better understand and treat your tumor.
Fuzhou, FujianAges 18 years+ - NCT06688188RecruitingEarly Phase 1
Study of 68Ga-JH12 PET/CT scan in solid tumors
This trial tests a new imaging agent, 68Ga-JH12, used during a PET/CT scan to see how it spreads through the body and how much radiation it gives off. It is for people with solid tumors who want to help researchers understand this better.
Fuzhou, FujianAges 18–80 - NCT06688305RecruitingEarly Phase 1
First human test of new PET scan agent for solid tumors
This trial tests a new imaging agent called 68Ga-NI-FAPI to see how well it works in a PET scan for people with different types of solid tumors. The goal is to help doctors better see and understand tumors.
Fuzhou, FujianAges 18–80 - NCT06734572RecruitingEarly Phase 1
PET/CT imaging study for solid tumors
This study uses a special PET/CT scan to see how a new imaging agent (18F-FAPIBiotin) spreads in the body and how much radiation it gives off. It's for people with confirmed solid tumors to help make future imaging more accurate.
Fuzhou, FujianAges 18–80 - NCT07146074Recruiting
Early radiation vs. observation for high-risk bone metastases
This trial tests whether giving radiation therapy early to high-risk but pain-free or nearly pain-free bone metastases can prevent future problems, compared to waiting and monitoring them. It is for people whose cancer has spread to multiple bones and who have certain risky features in those spots.
Wilrijk, AntwerpAges 18 years+ - NCT07058207Recruiting
Weight management program for obese cancer patients in treatment
This study offers a weight management program for people with obesity who are undergoing active cancer treatment (chemo or radiation) for a solid tumor. It aims to help you manage your weight while you fight cancer, and requires living in the Barcelona area.
L'Hospitalet de Llobregat, BarcelonaAges 18 years+ - NCT06606366Recruiting
Genetic tumor testing using a blood test to guide treatment
This study uses a simple blood test to look at the genetic makeup of your tumor. The results may help your doctors choose the best treatment for you. You will need to provide a tumor sample or have a biopsy.
NiceAges 18 years+ - NCT06504732RecruitingPhase 2/Phase 3
IAH0968 plus CAPEOX for HER2-positive gastric cancer
This trial tests a new drug (IAH0968) combined with chemotherapy (CAPEOX) for people with HER2-positive stomach or gastroesophageal junction cancer that has not been treated before or has spread.
Harbin, HeilongjiangAges 18–75 - NCT05802186Recruiting
AI-guided radiation plan for lung cancer tumors
This study uses an AI tool to help plan how doctors deliver focused radiation to lung tumors. It may help make radiation targeting more precise and support treatment safety for people with primary or limited metastatic lung cancer.
Chicago, IllinoisAges 18 years+ - NCT05753306RecruitingPhase 2
Robot surgery plus heated chemo for limited spread stomach cancer
This study tests a “robot-assisted” surgery to remove stomach cancer in the belly lining (peritoneum) along with heated chemotherapy placed inside the abdomen. It’s for people whose cancer has spread only in the peritoneum, aiming to control disease when there’s a good chance of removing it all.
Rochester, MinnesotaAges 18–80 - NCT05285358RecruitingPhase 1
Aerosol chemo plus standard drugs for bile duct and gallbladder cancer
This trial tests a new way to give the drug paclitaxel directly into your belly as a mist, along with two standard chemo drugs given through your veins, for bile duct or gallbladder cancer that has spread to the lining of the belly. The goal is to see if this approach can better control the cancer in the belly.
Duarte, CaliforniaAges 18 years+ - NCT04766515Recruiting
Study of immune checkpoint cancer treatment in real life
This is an observational study that follows adults with solid cancer who are receiving immune checkpoint inhibitor treatments. It aims to learn how these medicines are used and what outcomes may look like in everyday care.
ShanghaiAges 18 years+ - NCT03873064Recruiting
Weight and quality of life in cancer patients
This study looks at how body weight (measured as body mass index, or BMI) relates to quality of life in people with solid tumors. You would fill out questionnaires about how you feel, and the results may help doctors better support patients.
RomeAges 18 years+ - NCT02896335RecruitingPhase 2
Palbociclib and pembrolizumab for brain metastases
This study tests two drugs, palbociclib and pembrolizumab, for people whose solid tumors (like breast cancer or melanoma) have spread to the brain. The goal is to see if this combination can shrink or slow the growth of brain tumors that are progressing despite prior treatment.
Boston, MassachusettsAges 18 years+ - NCT02421380Recruiting
Tests how repeatable a special MRI scan is for tumors
This study checks whether a specialized MRI using injected “hyperpolarized pyruvate” gives consistent tumor images when repeated. It may help future patients by improving how reliably this scan can measure tumors.
Montvale, New JerseyAges 21–90 - NCT04104776RecruitingPhase 1/Phase 2
Test drug tulmimetostat for advanced cancers and lymphomas
This early-phase study tests tulmimetostat (DZR123) to shrink or control advanced solid tumors and certain lymphomas, and it may also test a combination in some prostate cancer groups. If you qualify, you’ll receive the study drug and be monitored closely, including blood tests and a request for tumor tissue to look for biomarkers.
Tampa, FloridaAges 18 years+ - NCT07525141RecruitingPhase 1
Testing JNJ-1761981 for advanced solid tumors
This early-stage trial tests a new drug called JNJ-1761981 in people with solid tumors (cancers that form in organs or tissues, excluding brain tumors) that have spread or returned after standard treatment. The study aims to find the right dose and see how well the drug works.
Jacksonville, FloridaAges 18 years+ - NCT06346041RecruitingEarly Phase 1
Testing a new IV drug IDOV-SAFE for advanced solid tumors
This trial tests a new intravenous drug called IDOV-SAFE in people with advanced solid tumors that have stopped responding to standard treatments or have no effective standard option. The goal is to see if it is safe and effective.
BeijingAges 18–75 - NCT05728957Recruiting
Biopsy and special scan for small kidney tumors
This trial studies using a kidney tumor biopsy and a special nuclear scan (SPECT/CT using sestamibi) to help evaluate kidney tumors before surgery. It may help doctors better characterize tumors that appear suspicious on imaging.
Maywood, IllinoisAges 18 years+ - NCT07277270RecruitingPhase 1
Study of a new drug with standard treatments for advanced solid tumors
This trial tests a new investigational drug called GSK5764227 when given along with standard cancer treatments or other drugs for people with advanced colorectal or prostate cancer that has spread and cannot be removed by surgery.
Reunion, FloridaAges 18 years+ - NCT06902350RecruitingPhase 1
Experimental drug CS231295 for advanced solid tumors
This trial tests an experimental drug called CS231295 for people with advanced solid tumors that have not responded to standard treatments. The purpose is to study safety and find out if the drug can shrink tumors.
Beijing, Beijing MunicipalityAges 18 years+ - NCT06395103RecruitingPhase 1/Phase 2
Zilovertamab vedotin for blood cancers and solid tumors
This trial tests a new drug called zilovertamab vedotin for children and young adults with certain blood cancers or solid tumors. The drug is designed to target and kill cancer cells, and the study will see if it is safe and effective.
Los Angeles, CaliforniaAges 6 months–25 years - NCT04192344RecruitingPhase 1
First test of an anti-cancer drug for advanced solid tumors
This Phase 1 study tests how safe a new drug (ABSK-021) is, what side effects it causes, and how the body processes it in people with advanced solid tumors. You may be eligible if your cancer has grown despite standard treatments or if no standard treatment exists.
Beverly Hills, CaliforniaAges 18 years+
Hear when a new Malignant Solid Neoplasm trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for malignant solid neoplasm?
- Yes. Clin2 currently lists 291 recruiting malignant solid neoplasm studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a malignant solid neoplasm trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a malignant solid neoplasm trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.